ADAG

Adagene (ADAG)

Adagene Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ADAG

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/08	06:00	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:ADAG	Adagene Inc
2024/11/08	06:00	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:ADAG	Adagene Inc
2024/11/08	00:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/11/08	00:01	GlobeNewswire Inc.	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc	NASDAQ:ADAG	Adagene Inc
2024/10/09	19:00	GlobeNewswire Inc.	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting	NASDAQ:ADAG	Adagene Inc
2024/09/24	23:26	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ADAG	Adagene Inc
2024/09/16	22:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/09/16	16:01	GlobeNewswire Inc.	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC	NASDAQ:ADAG	Adagene Inc
2024/08/29	20:00	GlobeNewswire Inc.	Adagene to Participate in Investor Conferences in September	NASDAQ:ADAG	Adagene Inc
2024/07/26	05:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/07/26	05:05	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2024/07/12	20:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September	NASDAQ:ADAG	Adagene Inc
2024/05/23	05:45	GlobeNewswire Inc.	Adagene to Present at Investor Conferences in June	NASDAQ:ADAG	Adagene Inc
2024/03/29	22:00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2024/03/08	06:01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
2024/03/02	06:30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
2024/02/27	22:00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
2024/02/09	20:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/02/09	20:00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
2024/01/17	07:01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
2024/01/17	07:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2024/01/04	19:00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
2023/11/04	01:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/11/04	01:00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
2023/10/12	21:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
2023/09/29	19:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/09/07	19:00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
2023/08/31	20:32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
2023/08/31	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
2023/07/08	05:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc